AMZN
Amazon.com, Inc.
AMZN has the edge over ARHS overall, supported by stronger valuation and stronger modeled upside.
ARHS
Arhaus, Inc.
ARHS's outlook is improving, though it still trails on the overall score.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
ARHS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Strong |
ARHS's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN has the edge over ARHS in the historical PE scenario, which offers more potential upside but is not a forecast.
ARHS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 10x | $4.81 | -64% |
| Fair | 18x | $8.20 | -39% |
| Expensive | 22x | $10.24 | -24% |
| Forward | 24x | $13.52 | — |
| Current | 29x | $13.52 | — |
Historical ranges are pointers, not guarantees.
ARHS's PE is in its expensive range at 29x. If earnings grow as analysts expect, today's price would be 24x next year's earnings.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for AMZN, with profitability improving.
ARHS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
ARHS has the edge over AMZN on the outlook, with more favorable valuation expectations.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over ARHS on earnings, with more consistent year-over-year improvement.
ARHS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.56 | +22% |
| Q3 2026 | $0.46 | -12% |
| Q2 2026 | $0.50 | 0% |
| Q1 2026 | $0.47 | +15% |
| Q4 2025 | $0.48 | -2% |
| Q3 2025 | $0.52 | -7.1% |
| Q2 2025 | $0.50 | -21% |
| Q1 2025 | $0.41 | -46% |
| Q4 2024 | $0.49 | -45% |
ARHS's earnings per share have fallen from their peak: $0.46 over the past year, against $1.13 in mid-2023.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over ARHS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over ARHS on profitability, with a higher operating margin.
ARHS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $368.1M | +6.8% |
| Q2 2026 | $384.9M | +7.4% |
| Q1 2026 | $314.3M | +0.9% |
| Q4 2025 | $364.8M | +5.1% |
| Q3 2025 | $344.6M | +8% |
| Q2 2025 | $358.4M | +16% |
| Q1 2025 | $311.4M | +5.5% |
| Q4 2024 | $347M | +0.9% |
ARHS's revenue has grown year over year for eight quarters in a row: $368M last quarter, up 6.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.7% | -2 points |
| Q2 2026 | 14% | +1 points |
| Q1 2026 | 0.7% | -1.1 points |
| Q4 2025 | 5.5% | -2.7 points |
| Q3 2025 | 4.8% | +1.4 points |
| Q2 2025 | 13% | +3.6 points |
| Q1 2025 | 1.7% | -4.5 points |
| Q4 2024 | 8.2% | -3.7 points |
ARHS's operating margin was 2.7% last quarter, down 2 points from the same quarter a year ago.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
ARHS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $91.9M | +228% |
| Q2 2026 | $48.3M | +131% |
| Q1 2026 | -$26.6M | -241% |
| Q4 2025 | -$8.8M | -168% |
| Q3 2025 | $28M | +509% |
| Q2 2025 | $20.9M | +86% |
| Q1 2025 | $18.9M | +73% |
| Q4 2024 | $13M | +$26.8M |
ARHS has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
ARHS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +467K shares |
| 1 year | +0.4% | +598K shares |
| 3 years | +1.5% | +2.1M shares |
| 5 years | +27% | +30.2M shares |
| Available history | +401% | +114M shares |
ARHS has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | $50,000 |
| Q1 2020 | $50,000 |
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
ARHS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -2.3x | Net Cash |
| Q2 2026 | -1.6x | Net Cash |
| Q1 2026 | -1.3x | Net Cash |
| Q4 2025 | -1.9x | Net Cash |
| Q3 2025 | -1.8x | Net Cash |
| Q2 2025 | -1.7x | Net Cash |
| Q1 2025 | -1.9x | Net Cash |
| Q4 2024 | -1.6x | Net Cash |
ARHS has the edge over AMZN on leverage, with a lower net debt burden relative to earnings.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
ARHS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.0 | Neutral |
| Stochastic | 90.6 | Overbought |
ARHS's weekly RSI is 69 (neutral) and its Stochastic is 91 (overbought).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN has the edge over ARHS on valuation relative to its sector.
ARHS PE vs Consumer Cyclical Sector
| Metric | ARHS | Sector median | Relative |
|---|---|---|---|
| PE | 29x | 18x | 63% above |
| PE % | 96 | 56 | 40 pts above |
ARHS is trading at 29x earnings, a 63% premium to the Consumer Cyclical sector's median of 18x.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN is in an uptrend: it's above all five of its weekly moving averages, and 40% above its 200-week average.
ARHS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.4 | 18% above |
| 20 week MA | $9.67 | 40% above |
| 50 week MA | $8.97 | 51% above |
| 100 week MA | $9.41 | 44% above |
| 200 week MA | $10.5 | 29% above |
ARHS has climbed back above all five of its weekly moving averages, and it's now 29% above its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has finished higher in five of the last six years, two of them by more than 50%. It's up 15% so far in 2026.
ARHS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $12.2 | $10.4 | -15% |
| 2022 | $10.4 | $9.24 | -11% |
| 2023 | $9.24 | $11.9 | +28% |
| 2024 | $11.9 | $9.26 | -22% |
| 2025 | $9.26 | $11.7 | +27% |
| 2026 YTD | $11.7 | $13.5 | +15% |
ARHS has the edge over AMZN on returns for 2026, with the stronger performance.